Salman Michael
Department of Paediatric Neurosciences, King's College Hospital, London, UK.
Eur J Paediatr Neurol. 2002;6(4):213-9. doi: 10.1053/ejpn.2002.0596.
The objective was to evaluate the effects of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome. The study design was a systematic review of randomized controlled trials of dietary supplements and/or drugs reporting any assessment of cognitive function in subjects with Down syndrome. Eleven trials were identified with 373 randomized participants. None of the trials reported cognitive enhancing effect in subjects with Down syndrome. Meta-analysis was not conducted due to the heterogeneous nature of the population, interventions and outcome measures used. Overall, the quality of the trials was poor with few subjects and generally inadequate allocation concealment of the treatments given. This comprehensive systematic review provides no positive evidence that any combination of drugs, vitamins and minerals enhance either cognitive function or psychomotor development in people with Down syndrome. However, because of the small number of subjects involved and the overall unsatisfactory quality of the trials, an effect cannot be excluded at this point. At present there is no justification for the use of such regimes outside the context of large well designed trials. Parents of children with Down syndrome should be actively discouraged from giving these 'miracle drugs' to their children.
目的是评估治疗性膳食补充剂和药物对唐氏综合征患者认知功能的影响。研究设计为对膳食补充剂和/或药物的随机对照试验进行系统评价，这些试验报告了对唐氏综合征患者认知功能的任何评估。共识别出11项试验，有373名随机参与者。没有一项试验报告对唐氏综合征患者有认知增强作用。由于所使用人群、干预措施和结局指标的异质性，未进行荟萃分析。总体而言，试验质量较差，受试者数量少，且所给予治疗的分配隐藏通常不充分。这项全面的系统评价没有提供积极证据表明任何药物、维生素和矿物质的组合能增强唐氏综合征患者的认知功能或精神运动发育。然而，由于涉及的受试者数量较少且试验的总体质量不令人满意，目前不能排除存在某种效果。目前，在大型精心设计的试验之外，没有理由使用此类疗法。应积极劝阻唐氏综合征患儿的家长给孩子服用这些“神奇药物”。
